|
| | Publication Year | Title | Author(s) |
| 1 | 6-Oct-2014 | Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. | Johnson, Douglas B; Flaherty, Keith T; Weber, Jeffrey S; Infante, Jeffrey R; Kim, Kevin B; Kefford, Richard F; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan S ; Sharfman, William H; McWilliams, Robert R; Sznol, Mario; Lawrence, Donald P; Gibney, Geoffrey T; Burris, Howard A; Falchook, Gerald S; Algazi, Alain; Lewis, Karl; Long, Georgina V; Patel, Kiran; Ibrahim, Nageatte; Sun, Peng; Little, Shonda; Cunningham, Elizabeth; Sosman, Jeffrey A; Daud, Adil; Gonzalez, Rene |
| 2 | 1-Apr-2014 | A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. | Lau, David K ; Andrews, Miles C; Turner, Natalie; Azad, Arun A; Davis, Ian D; Cebon, Jonathan S |
| 3 | 11-Oct-2013 | Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. | Anaka, Matthew; Hudson, Christopher; Lo, Pu-Han; Do, Hongdo; Caballero, Otavia L; Davis, Ian D; Dobrovic, Alexander ; Cebon, Jonathan S ; Behren, Andreas |
| 4 | 23-Jul-2013 | The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. | John, Thomas ; Starmans, Maud H W; Chen, Yao-Tseng; Russell, Prudence A; Barnett, Stephen A ; White, Shane C; Mitchell, Paul L R ; Walkiewicz, Marzena; Azad, Arun A; Lambin, Philippe; Tsao, Ming-Sound; Deb, Siddhartha; Altorki, Nasser; Wright, Gavin; Knight, Simon R ; Boutros, Paul C; Cebon, Jonathan S |
| 5 | 11-Apr-2013 | The Ludwig institute for cancer research Melbourne melanoma cell line panel. | Behren, Andreas; Anaka, Matthew; Lo, Pu-Han; Vella, Laura J; Davis, Ian D; Catimel, Jenny; Cardwell, Tracy; Gedye, Craig; Hudson, Christopher; Stan, Rodica; Cebon, Jonathan S |
| 6 | 27-Feb-2013 | Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein. | Komatsu, Nobukazu; Jackson, Heather M; Chan, Kok-fei; Oveissi, Sara; Cebon, Jonathan S ; Itoh, Kyogo; Chen, Weisan |
| 7 | 1-Feb-2012 | Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile. | Anaka, Matthew; Freyer, Claudia; Gedye, Craig; Caballero, Otavia; Davis, Ian D; Behren, Andreas; Cebon, Jonathan S |
| 8 | 23-Jun-2011 | Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™. | Nicholaou, Theo; Chen, Weisan; Davis, Ian D; Jackson, Heather M; Dimopoulos, Nektaria; Barrow, Catherine; Browning, Judy; Macgregor, Duncan; Williams, David; Hopkins, Wendie; Maraskovsky, Eugene; Venhaus, Ralph; Pan, Linda; Hoffman, Eric W; Old, Lloyd J; Cebon, Jonathan S |
| 9 | 4-Nov-2010 | Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. | Svobodová, Suzanne; Browning, Judy; MacGregor, Duncan; Pollara, Gabriele; Scolyer, Richard A; Murali, Rajmohan; Thompson, John F; Deb, Siddhartha; Azad, Arun A; Davis, Ian D; Cebon, Jonathan S |
| 10 | 10-Mar-2009 | Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. | Davis, Ian D; Brady, Ben; Kefford, Richard F; Millward, Michael; Cebon, Jonathan S ; Skrumsager, Birte K; Mouritzen, Ulrik; Hansen, Lasse Tengbjerg; Skak, Kresten; Lundsgaard, Dorthe; Frederiksen, Klaus Stensgaard; Kristjansen, Paul E G; McArthur, Grant A |
| 11 | 10-Mar-2009 | Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. | Nicholaou, Theo; Ebert, Lisa M; Davis, Ian D; McArthur, Grant A; Jackson, Heather M; Dimopoulos, Nektaria; Tan, Bee; Maraskovsky, Eugene; Miloradovic, Lena; Hopkins, Wendie; Pan, Linda; Venhaus, Ralph; Hoffman, Eric W; Chen, Weisan; Cebon, Jonathan S |
| 12 | 15-Aug-2008 | Predicting clinical outcome through molecular profiling in stage III melanoma. | John, Thomas ; Black, Michael A; Toro, Tumi T; Leader, Debbie; Gedye, Craig A; Davis, Ian D; Guilford, Parry J; Cebon, Jonathan S |
| 13 | 15-Jun-2007 | An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. | Davis, Ian D; Skrumsager, Birte K; Cebon, Jonathan S ; Nicholaou, Theo; Barlow, John W; Moller, Niels Peter Hundahl; Skak, Kresten; Lundsgaard, Dorthe; Frederiksen, Klaus Stensgaard; Thygesen, Peter; McArthur, Grant A |
| 14 | 10-Sep-2006 | Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. | Davis, Ian D; Chen, Qiyuan; Morris, Leone; Quirk, Juliet; Stanley, Maureen; Tavarnesi, Maria L; Parente, Phillip; Cavicchiolo, Tina; Hopkins, Wendie; Jackson, Heather M; Dimopoulos, Nektaria; Tai, Tsin Yee; MacGregor, Duncan; Browning, Judy; Svobodova, Suzanne; Caron, Dania; Maraskovsky, Eugene; Old, Lloyd J; Chen, Weisan; Cebon, Jonathan S |
| 15 | 19-Nov-2005 | A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. | Gan, Hui K ; Mitchell, Paul L R ; Galettis, Peter; Davis, Ian D; Cebon, Jonathan S ; de Souza, Paul; Links, Matthew |
| 16 | 8-Jul-2005 | Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma. | Harris, Marion T; Berlangieri, Salvatore U ; Cebon, Jonathan S ; Davis, Ian D; Scott, Andrew M |
| 17 | 16-Nov-2004 | Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. | Schnurr, Max; Chen, Qiyuan; Shin, Amanda; Chen, Weisan; Toy, Tracey; Jenderek, Corinna; Green, Simon; Miloradovic, Lena; Drane, Debbie; Davis, Ian D; Villadangos, Jose; Shortman, Ken; Maraskovsky, Eugene; Cebon, Jonathan S |
| 18 | 23-Sep-2004 | The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. | Shackleton, Mark; Davis, Ian D; Hopkins, Wendie; Jackson, Heather M; Dimopoulos, Nektaria; Tai, Tsin; Chen, Qiyuan; Parente, Phillip; Jefford, Michael; Masterman, Kelly-Anne; Caron, Dania; Chen, Weisan; Maraskovsky, Eugene; Cebon, Jonathan S |
| 19 | 16-Jul-2004 | The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning. | Vaughan, Hilary A; St Clair, Fiona; Scanlan, Matthew J; Chen, Yao-Tsen; Maraskovsky, Eugene; Sizeland, Andrew; Old, Lloyd J; Cebon, Jonathan S |
| 20 | 1-Apr-2004 | A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. | Mitchell, Paul L R ; Basser, R L; Chipman, M; Grigg, Andrew P ; Mansfield, R; Cebon, Jonathan S ; Davis, Ian D; Appia, F; Green, M |
Loading...
2
0
20
0
false
0000-0002-3898-950x